Literature DB >> 20472991

Non-renal indications for continuous renal replacement therapy: current status in Japan.

Shigeto Oda, Tomohito Sadahiro, Yo Hirayama, Masataka Nakamura, Eizo Watanabe, Yoshihisa Tateishi, Hiroyuki Hirasawa.   

Abstract

Continuous renal replacement therapy (CRRT) has been extensively used in Japan as renal support for critically ill patients managed in the ICU. In Japan, active research has also been conducted on non-renal indications for CRRT, i.e. the use of CRRT for purposes other than renal support. Various methods of blood purification have been attempted to remove inflammatory mediators, such as cytokines, in patients with severe sepsis or septic shock. In these attempts, efficacy was demonstrated for continuous hemodiafiltration(CHDF) using a polymethyl methacrylate (PMMA) membrane hemofilter which is capable of adsorbing and removing various cytokines, plasma diafiltration, and online CHDF. Furthermore, a recently developed cytokine-adsorbing column is now under clinical evaluation. Definite evidence for the efficacy of CRRT for non-renal indications has not been established. In evaluating the efficacy of CRRT for non-renal indications, it is essential to focus on patients subjected to be studied, such as severe sepsis or septic shock, and to evaluate its indication, commencement, termination of therapy and also its therapeutic effects based on analysis of blood levels of the target substances to be removed (e.g. cytokines). IL-6 blood level appears to be useful as a variable for this evaluation. It is expected that evidence endorsing the validity of these methods now being attempted in Japan will be reported near future. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20472991     DOI: 10.1159/000314851

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN: 0302-5144            Impact factor:   1.580


  7 in total

1.  The Japanese guidelines for the management of sepsis.

Authors:  Shigeto Oda; Mayuki Aibiki; Toshiaki Ikeda; Hitoshi Imaizumi; Shigeatsu Endo; Ryoichi Ochiai; Joji Kotani; Nobuaki Shime; Osamu Nishida; Takayuki Noguchi; Naoyuki Matsuda; Hiroyuki Hirasawa
Journal:  J Intensive Care       Date:  2014-10-28

2.  Clinical study of blood purification therapy in critical care in Japan: results from the survey research of the Japan Society for Blood Purification in Critical Care in 2013.

Authors:  Toshiaki Arimura; Masanori Abe; Hidetoshi Shiga; Hiroshi Katayama; Kazo Kaizu; Shigeto Oda
Journal:  J Artif Organs       Date:  2017-06-09       Impact factor: 1.731

3.  Cardiorenal syndromes and sepsis.

Authors:  C Chelazzi; G Villa; A R De Gaudio
Journal:  Int J Nephrol       Date:  2011-03-30

4.  Effects of continuous renal replacement therapy on intestinal mucosal barrier function during extracorporeal membrane oxygenation in a porcine model.

Authors:  Changsheng He; Shuofei Yang; Wenkui Yu; Qiyi Chen; Juanhong Shen; Yimin Hu; Jialiang Shi; Xingjiang Wu; Jieshou Li; Ning Li
Journal:  J Cardiothorac Surg       Date:  2014-04-23       Impact factor: 1.637

5.  Septic shock due to Aeromonas hydrophila bacteremia in a patient with alcoholic liver cirrhosis: a case report.

Authors:  Tetsuya Yumoto; Shingo Ichiba; Nao Umei; Sunao Morisada; Kohei Tsukahara; Keiji Sato; Toyomu Ugawa; Yoshihito Ujike
Journal:  J Med Case Rep       Date:  2014-12-03

6.  Effects of Early Continuous Venovenous Hemofiltration on E-Selectin, Hemodynamic Stability, and Ventilatory Function in Patients with Septic-Shock-Induced Acute Respiratory Distress Syndrome.

Authors:  Jian-Biao Meng; Zhi-Zhen Lai; Xiu-Juan Xu; Chun-Lian Ji; Ma-Hong Hu; Geng Zhang
Journal:  Biomed Res Int       Date:  2016-12-01       Impact factor: 3.411

7.  PK/PD analysis of biapenem in patients undergoing continuous hemodiafiltration.

Authors:  Gaku Akashita; Yuto Hosaka; Toru Noda; Kazuya Isoda; Tsutomu Shimada; Kazuki Sawamoto; Ken-Ichi Miyamoto; Takumi Taniguchi; Yoshimichi Sai
Journal:  J Pharm Health Care Sci       Date:  2015-11-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.